sublingual misoprostol on intraoperative blood loss prior to abdominal hysterectomy.
Phase 1
- Conditions
- Hysterectomy.N99-N99 Other disorders of the genitourinary systemXIV Diseas
- Registration Number
- IRCT201610224025N8
- Lead Sponsor
- Vice President of Research Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
all women undergoing abdominal hysterectomy for benign gynecologic disease and Exclusion criteria include patients who have contraindications to misoprostol, including mitral stenosis, heart disease, glaucoma, sickle cell anemia, severe hypertension, diastolic blood pressure above 100 mm /Hg, severe asthma, or known hypersensitivity to prostaglandins, known endometriosis patients with a history of pelvic or active disease, diabetes, obesity (BMI> 30), a history of previous myomectomy and previous use of GnRH agonists before surgery, patients with invasive cancer endometrial, cervical and ovarian tumors.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood loss. Timepoint: intra operative. Method of measurement: Total blood volume in the suction bottle + weight difference between dry and wet gauze.
- Secondary Outcome Measures
Name Time Method Postoperative hemoglobin. Timepoint: 24 hours after surgery. Method of measurement: blood test.;Degree of fever after surgery. Timepoint: 24 hours after surgery. Method of measurement: Thermometer.;Length of stay in hospital. Timepoint: From admission to exit. Method of measurement: day.;The need for blood transfusions. Timepoint: Intraoperative and postoperative. Method of measurement: On hemoglobin level and Severity of bleeding.